本文選題：中西醫(yī)結(jié)合 + 扶正法��； 參考：《中華中醫(yī)藥學(xué)刊》2015年11期

【摘要】：目的:觀察中西醫(yī)結(jié)合治療晚期非小細胞肺癌(NSCLC)的臨床療效,以建立晚期非小細胞肺癌中西醫(yī)結(jié)合臨床優(yōu)化治療方案。方法:134例晚期NSCLC患者分為4組,正虛對照組(33例)、邪實對照組(33例)予順鉑(DDP)+多西紫杉醇(Doc)化療;正虛觀察組(34例)、邪實觀察組(34例)在化療基礎(chǔ)上,正虛為主型予參芪扶正注射液和芪貞固本方;邪實為主型予苦參堿注射液和芩蓮正積方。兩周期后,比較兩組患者治療效果,觀察1年,比較1年生存率。結(jié)果:與對照組相比,各觀察組可明顯提高腫瘤控制率、增加卡氏評分和體質(zhì)量、降低癥狀積分和腫瘤標志物(CEA、CA19-9)、提高1年生存率、減輕消化道反應(yīng)(P0.05);扶正觀察組與其對照組相比可明顯增強患者免疫功能,減輕骨髓抑制(P0.05)。結(jié)論:本研究所采用中西醫(yī)結(jié)合治療方案具有良好的治療效果,能減毒增效,與單純化療相比有顯著優(yōu)勢,值得臨床廣泛推廣。
[Abstract]:Objective: to observe the clinical effect of combination of traditional Chinese and western medicine in the treatment of advanced non-small cell lung cancer (NSCLC), and to establish an optimized regimen of integrated traditional Chinese and western medicine for advanced non-small cell lung cancer (NSCLC). Methods one hundred and thirty-four patients with advanced NSCLC were divided into 4 groups: positive deficiency control group (33 cases), evil solid control group (33 cases) received DDP docetaxel (Doc) chemotherapy, positive deficiency observation group (34 cases) and evil solid observation group (34 cases) were treated with chemotherapy. Shenqi Fuzheng injection and Qizhen Guben prescription were given to the main type of deficiency, while Matrine injection and Qinlian Zhengji prescription were used as the main type of evil. After two cycles, the therapeutic effects, 1-year and 1-year survival rates were compared between the two groups. Results: compared with the control group, the control rate of tumor in each observation group was significantly increased, the Cardner score and body mass were increased, the symptom score and tumor marker (CEACA19-9) were decreased, and the 1-year survival rate was increased. Reduce digestive tract reaction (P0.05); Fuzheng observation group compared with its control group can significantly enhance the immune function of patients reduce bone marrow suppression (P0.05). Conclusion: the combination of traditional Chinese and western medicine has a good therapeutic effect, can reduce toxicity and increase efficiency, and has significant advantages compared with chemotherapy alone. It is worth popularizing in clinic.
【作者單位】： 山東中醫(yī)藥大學(xué)附屬醫(yī)院;山東中醫(yī)藥大學(xué);
【基金】：山東省中醫(yī)藥科技發(fā)展計劃(2009Z003)
【分類號】：R734.2

【參考文獻】

相關(guān)期刊論文 前8條

1 李偉;周彩存;;晚期非小細胞肺癌化療新進展[J];癌癥進展;2009年04期

2 吳一龍,張明和,廖美琳,周清華,蔣國，

本文編號：2089101